Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is absorbed into the skin and converted into protoporphyrin IX. When the area is exposed to a specific wavelength of red light, protoporphyrin IX generates reactive oxygen species that selectively destroy abnormal keratinocytes while sparing healthy tissue.

The dosage and application schedule for Metvix are determined by the prescribing clinician based on the extent and location of the actinic keratosis lesions. Patients should follow the healthcare professional’s instructions precisely.

Safety data for Metvix in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metvix (methyl aminolevulinate) is a second‑generation photosensitizer that typically requires a shorter incubation time and lower light dose compared with older agents such as 5‑aminolevulinic acid. This can result in a more convenient treatment schedule and potentially reduced discomfort.

Metvix should be stored at room temperature, protected from direct light and moisture, and kept in its original packaging until use. Do not freeze or expose the product to extreme temperatures.

Metvix is applied topically to the affected skin area by a healthcare professional. After a prescribed incubation period, the area is illuminated with a calibrated red‑light source to activate the photosensitizer and initiate the therapeutic effect.

Serious risks include severe phototoxic reactions, secondary infections of the treated site, persistent scarring, and rare allergic responses such as angioedema. Patients should report any unexpected or worsening symptoms to their clinician promptly.

Metvix is contraindicated in individuals with known hypersensitivity to methyl aminolevulinate or any component of the formulation, as well as in patients with active skin infections or extensive open wounds at the intended treatment site.